Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs globally provides a wide range of high-quality anti-IGF1R recombinant antibodies. These antibodies are precisely produced through advanced biotechnological procedures to assure maximum performance in a variety of research applications. Our cutting-edge platform leverages the most recent advances in antibody engineering and production, ensuring superior specificity, stability, and effectiveness. Furthermore, our experienced staff is dedicated to serving the scientific community by offering both high-quality products and outstanding customer service. We provide individual advice and technical knowledge to help researchers optimize their experimental designs and achieve their research objectives.
The development and metastasis of cancer are significantly influenced by the insulin-like growth factor (IGF) axis. Among its constituents, the type 1 IGF receptor (IGF-1R) stands out as a critical component, known for its cancer-promoting actions across several cancer types. Specifically, IGF-1R promotes tumor development, metastasis, and resistance to cancer therapy. Given its importance in cancer etiology, IGF-1R is seen as a prospective target for cancer therapeutic development.
Insulin-like growth factor 1 (IGF-1) receptor; insulin like growth factor 1 receptor; IGF-1R; CD221; IGFIR; IGFR; JTK13.
This receptor binds insulin-like growth factors with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively, spliced transcript variants encoding distinct isoforms have been found for this gene.
Creative Biolabs provides a wide range of recombinant anti-IGF1R antibodies that have been rigorously developed to provide maximum specificity and affinity. These antibodies are available in a variety of forms, each designed to assist a wide range of research and therapeutic goals, from fundamental studies to the development of breakthrough healthcare products. We employ our sophisticated platform to deliver breakthrough tools that drive research in immunology, cancer biology, and related domains, as well as accelerate the advancement of therapeutic innovation.
Table 1. Featured anti-IGF1R recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-199 | Human Anti-IGF1R Recombinant Antibody (TAB-199) | Human | Human IgG1, κ | FC, IP, ELISA, Neut, FuncS, IF, ICC, Inhib, WB, Activ, IHC, Block |
TAB-736 | Anti-IGF1R Recombinant Antibody (Dalotuzumab) | Human | Mouse IgG1 - kappa | FC, IP, ELISA, Neut, FuncS, IF, ICC, WB, Activ, Inhib |
TAB-014ZJ | Mouse Anti-IGF1R Recombinant Antibody (TAB-014ZJ) | Human | Mouse IgG1 | ELISA, FC, Inhib, IP |
TAB-078 | Anti-Human IGF1 Receptor Recombinant Antibody (Cixutumumab) | Human | Human IgG1 - lambda | IP, Neut, FuncS, ELISA, FC, WB, IHC, Stim, IF, Block |
TAB-052ZJ | Anti-Human IGF-1R Recombinant Antibody (18) | Human | Human antibody | IHC, ELISA, FC, IF, IP |
Creative Biolabs provides an extensive range of rigorously tested anti-IGF1R recombinant antibodies. Our advanced facilities and skilled scientists meticulously develop each antibody to precisely target IGF1R, and we conduct thorough testing and validation to ensure that these antibodies display exceptional specificity, robust binding affinity, and optimal properties for diverse research applications.
Fig.1 ELISA analysis of anti-IGF1R antibody
(Cat# TAB-199, Creative Biolabs).
Fig.2 HPLC analysis of anti-IGF1R antibody
(Cat# TAB-014ZJ, Creative Biolabs).
Fig.3 WB analysis of anti-IGF1R antibody
(Cat# TAB-078, Creative Biolabs).
Fig.4 WB analysis of anti-IGF1R antibody
(Cat# TAB-199, Creative Biolabs).
Creative Biolabs provides an excellent supply of high-quality anti-IGF1R antibodies generated through cutting-edge genetic techniques.
Featured Anti-IGF1R Recombinant Antibody Production Platforms
Fig.5 Milligram-scale anti-IGF1R recombinant antibody production.
Fig.6 Gram-scale anti-IGF1R recombinant antibody production.
Creative Biolabs delivers a broad selection of top-tier anti-IGF1R recombinant antibodies in various formats, catering to the diverse needs of researchers worldwide.
Fig.7 Full-length anti-IGF1R recombinant antibody production and modalities.
Table 2. Public drug targeting IGF1R.
Company | Research Phase | Classification | Condition |
Amgen Chugai Pharmaceutical Genmab (Originator) Horizon Pharma (Amgen) Horizon Therapeutics (Amgen) River Vision (Amgen) Roche |
Launched - 2020 |
Cancer Immunotherapy Human Monoclonal Antibodies |
Cancer Cancer, breast Cancer, breast, metastatic Cancer, lung (non-small cell) (NSCLC) Cancer, solid tumor Diabetic macular edema Sarcoma Thyroid-associated ophthalmopathy (Graves ophthalmopathy) |
Astellas Pharma (Originator) Fujisawa (Astellas Pharma) OrphanPacific |
Launched - 1995 |
Insulin-Like Growth Factor-1 (IGF-1) Polypeptides, from 41 AA Recombinant proteins |
Diabetes Growth hormone deficit |
Biogen (Originator) Pfizer (Originator) |
Registered - 1994 |
Insulin-Like Growth Factor-1 (IGF-1) Polypeptides, from 41 AA Recombinant proteins |
Diabetes |
Innovent Biologics (Originator) | Pre-Registered | Monoclonal Antibodies |
Autoimmune disease Thyroid-associated ophthalmopathy (Graves ophthalmopathy) |
Cephalon (Teva) Chiron (Novartis Vaccines and Diagnostics) Kyowa Kirin Novartis Vaccines and Diagnostics Teva (Originator) |
Pre-Registered |
Insulin-Like Growth Factor-1 (IGF-1) Polypeptides, from 41 AA Recombinant proteins |
Amyotrophic lateral sclerosis Osteoarthritis Other neurological disorders |
Amgen (Originator) Cancer International Research Group Dana-Farber Cancer Institute ImmunityBio NantCell (ImmunityBio) National Cancer Institute National Cancer Institute (NCI) (National Cancer Institute) Takeda |
Phase III |
Cancer Immunotherapy Human Monoclonal Antibodies |
Cancer Cancer, breast Cancer, colorectal, metastatic Cancer, lung (small cell) (SCLC) Cancer, ovary Cancer, ovary (epithelial) Cancer, pancreas (adenocarcinoma) Cancer, pancreas (adenocarcinoma) metastatic Cancer, pancreas, metastatic Cancer, solid tumor Neuroendocrine cancer Non-Hodgkin lymphoma Rhabdomyosarcoma Sarcoma, Ewing Soft tissue sarcoma |
ImmunoGen (Originator) Sanofi sanofi-aventis (Sanofi) Viridian Therapeutics Zenas BioPharma |
Phase III |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer Cancer, breast Cancer, liver Cancer, solid tumor Multiple myeloma Thyroid-associated ophthalmopathy (Graves ophthalmopathy) |
Memorial Sloan-Kettering Cancer Center Merck & Co Merck & Co. (Merck & Co) Pierre Fabre (Originator) |
Phase II/III |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer Cancer, breast Cancer, colorectal, metastatic Cancer, lung (non-small cell) (NSCLC) Cancer, pancreas (adenocarcinoma) Multiple myeloma Neuroendocrine cancer |
ImVax Thomas Jefferson University (Originator) |
Phase II |
Antisense Therapy Cancer Immunotherapy Cancer Vaccines Cell Therapy Single-stranded oligodeoxyribonucleotide (DNA) |
Astrocytoma Cancer, brain Glioblastoma Glioma |
ImClone (Lilly) Lilly (Originator) National Cancer Institute National Cancer Institute (NCI) (National Cancer Institute) National Cancer Institute (US) (National Cancer Institute) University of Chicago University of Washington |
Phase II |
Cancer Immunotherapy Human Monoclonal Antibodies |
Acute lung injury Cancer, breast Cancer, breast, metastatic Cancer, colorectal, metastatic Cancer, esophagus Cancer, head and neck Cancer, head and neck (squamous cell carcinoma) Cancer, liver Cancer, liver (hepatocellular carcinoma) Cancer, lung (non-small cell) (NSCLC) Cancer, lung (non-small cell) (NSCLC), metastatic Cancer, lung (small cell) (SCLC) Cancer, pancreas Cancer, pancreas, metastatic Cancer, prostate, metastatic Cancer, solid tumor Cancer, thymus Fibrosis Lymphoma Melanoma, uveal Mesothelial tumor Neuroendocrine cancer Sarcoma Soft tissue sarcoma |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
As a leading provider of biotechnology research services, Creative Biolabs is dedicated to offering an extensive array of premium anti-IGF1R recombinant antibodies. For further details or inquiries about our products, feel free to reach out to us at your convenience.